RecruitingPhase 2NCT06222671

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of 608 in Patients With Non-radiographic Axial Spondyloarthritis (Nr-axSpA)


Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Enrollment

180 participants

Start Date

Mar 22, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study will evaluate the effect and safety of 608 in patients with nr-axSpA.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Female and male patients at least 18 years of age at the time of screening.
  • Diagnosis of axial spondyloarthritis according to Ankylosing Spondylo Arthritis International Society (ASAS) axial spondyloarthritis criteria
  • Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)
  • Total back pain as measured by NRS ≥ 4 at baseline

Exclusion Criteria6

  • Patients with other uncontrolled active inflammatory diseases.
  • Clinical laboratory tests and other tests that reveal abnormalities with clinical significance
  • Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.
  • History of cancer.
  • Known or suspected history of immunosuppression.
  • Known with allergic or intolerant to mometasone furoate spray or 608/placebo.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG608

608 subcutaneous (SC) injection.

DRUG608

608 subcutaneous (SC) injection.

DRUGPlacebo

Placebo subcutaneous (SC) injection.


Locations(6)

Site 01

Beijing, Beijing Municipality, China

Site 03

Beijing, Beijing Municipality, China

Site 05

Chongqing, Chongqing Municipality, China

Site 02

Zhengzhou, Henan, China

Site 04

Nanjing, Jiangsu, China

Site 06

Shenzhen, Shenzhen, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06222671


Related Trials